Seagen

Youtube Subscribe

Open: 212.72 Close: 213.13 Change: 0.41

The best way to get informed about Seagen without reading hundreds of pages.

How much time have you spent trying to decide whether investing in Seagen? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Seagen are: Seagen, cancer, …

Concept Map

Semantic Network

Stock Summary

Seagen Inc. develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors. It has collaboration agreements with Takeda.

Today's Summary

Pfizer CFO reiterates Seagen closing expected later this year, early next year. European antitrust regulator approved purchase last month. FDA grants priority review for supplemental biologics license application.

Today's News

Seagen - FDA grants priority review for supplemental biologics license application (sbla) of padcev® (enfortumab vedotin-ejfv) with keytruda® (pembrolizumab) for first-line treatment of advanced bladder cancer. Pfizer CFO reiterates Seagen closing expected later this year, early next year. Pfizer is working diligently to close the Seagen ( SGEN ) deal, Denton said at Evercore ISSs 6th Annual HealthConx Conference on Tuesday. European antitrust regulator approved purchase last month. Seagen is committed to advancing late-stage clinical trials and expanding the development of its portfolio both in and outside the U.S. Gain practical experience through educational and social events, while helping us create meaningful change in cancer care. Seagen and Astellas entered a clinical collaboration agreement with Merck to evaluate the combination of PADCEV and KEYTRUDA in patients with previously untreated metastatic urothelial cancer. The FDA has set a target action date of May 9, 2024. Pfizer (PFE.N) is in the middle of buying ADC pioneer Seagen in a $43 billion deal. Merck last month said it would pay Japanese drugmaker $5.

Stock Profile

"Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington."

Keywords

This document will help you to evaluate Seagen without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Seagen are: Seagen, cancer, Pfizer, FDA, advance, year, deal, and the most common words in the summary are: seagen, job, market, research, cancer, inc, ftse, . One of the sentences in the summary was: European antitrust regulator approved purchase last month. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #seagen #job #market #research #cancer #inc #ftse.

Read more →

Youtube Subscribe

---